Purpose/Objectives: To provide an overview of the evidence that supports a role for the proinfl ammatory cytokines interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a), and interleukin-6 (IL-6) in the etiology of cancer chemotherapy-related symptoms.
Lisa J. Wood, PhD, BSN, is an assistant professor in the School of Nursing at the Oregon Health and Science University (OHSU) Cancer Institute in Portland; and Lillian M. Nail, PhD, RN, FAAN, ➤ The idea of a common underlying mechanism for several chemotherapy-related symptoms contributed to current interest in understanding the structure of the relationships among concurrent symptoms, often referred to as symptom clusters, and also generated concern that the long-standing tradition of studying symptoms in isolation may have obscured the possibility that the symptoms might be produced by the same mechanism. P atients undergoing cancer chemotherapy with mechanistically distinct drugs display many of the classic symptoms of sickness behavior caused by the production of the proinfl ammatory cytokines interleukin-1 b (IL-1 ), tumor necrosis factor-a (TNF-), and interleukin-6 (IL-6) by macrophages and other immune cells in response to an immune challenge (Bluthe, Laye, et al., 2000; Bluthe, Michaud, Poli, & Dantzer, 2000) . For instance, similar to people with viral or bacterial infections, patients with cancer complain of fatigue, experience loss of appetite and pain, and suffer sleep disturbance (Lee, Dantzer, et al., 2004) . Prolonged production of proinfl ammatory cytokines also can lead to a variety of symptoms, including anemia (Means, 2004) , fat and muscle wasting (cachexia) (Argiles, Busquets, & Lopez-Soriano, 2005) , and depression (Anisman, Merali,
Cancer Chemotherapy-Related Symptoms:
Evidence to Suggest a Role for Proinfl ammatory Cytokines
